Additional source of lignans. “Schisandrin®” has a pronounced hepatoprotective, anti-inflammatory and immunomodulatory effect, improves metabolic status, and has a multifaceted antioxidant effect.
Indications for use: • non-alcoholic fatty liver disease (including non-alcoholic steatosis, non-alcoholic steatohepatitis with signs of liver fibrosis); • non-alcoholic fatty liver disease in patients in combination with type II diabetes mellitus; • toxic hepatitis (alcohol-related, drug-related, caused by taking medications); • in patients with ineffectiveness of previously administered courses of antiviral therapy for chronic viral hepatitis B and C and as an accompanying therapy for chronic viral hepatitis B and C; • women with polycystic ovary syndrome (PCOS) and overweight to prevent metabolic disorders.
According to published data and research conducted: “New possibilities for the treatment of non-alcoholic steatohepatitis” Fadeenko G.D., Kolesnikova O.V., Solomentseva T.A., Modern Gastroenterology, No. 1 (99), 2018; “A look at liver fibrosis in the light of understanding the modern mechanisms of its development” Kolesnikova O.V., Gastroenterology, No. 2, 2019; Dorofeev A.E., Rudenko N.N., Tkach S.M., Shvets O.V., Cheverda T.L., Gastroenterology, No. 4, 2019; “Polycystic ovary syndrome: an approach to the correction of metabolic disorders” Kalugina L.V., Tatarchuk T.F., Reproductive Endocrinology, No. 2 (52), 2020:
Schisandrin is a multifunctional plant adaptogen, the active substance of which is schisandrin, a biologically active compound of the lignan group of Schisandra chinensis. Under the influence of schisandrin, the functions of hepatocytes are restored in case of liver lesions of various etiologies, the level of liver enzymes is normalized, and the activity of markers of cytolysis, cholestasis, and immune inflammation is reduced.
“Schisandrin” restores pathomorphological disorders of the structure of the liver tissue, reduces the activity of the cytolytic enzymes ALT and AST, suppresses the production of highly sensitive C-reactive protein (CRP), tumor necrosis factor (TNF-α) by active neutrophils, Kupffer’s; helps reduce free radical processes, suppress oxidative stress caused by impaired mitochondrial function, thereby preventing necrosis and apoptosis of hepatocytes.
“Schisandrin®” slows down the progression of inflammation and prevents the formation of more severe stages of liver fibrosis, helps reduce the manifestations of symptoms of liver dysfunction (heaviness in the right hypochondrium, dyspeptic symptoms, including flatulence, loss of appetite, bitterness in the mouth), reduce signs of asthenic syndrome, increase tolerance to physical activity in patients with steatohepatitis.
“Schisandrin®” improves metabolic status – has a hypoglycemic effect, reduces the HOMA index, body mass index (BMI), reduces the level of HbA1C, total cholesterol and triglycerides. In women with polycystic ovary syndrome (PCOS), Schizandrin helps correct metabolic disorders, improve the menstrual cycle, and reduce the frequency of androgen-dependent dermopathy.
Adults: 1-2 tablets three times a day after meals. Do not exceed the recommended daily intake. The course of admission is 3-6 months. In the future, the duration of use should be agreed with your doctor. Before use, consultation with a doctor is recommended.
CONTRAINDICATIONS
Individual sensitivity to components, pregnancy, breastfeeding, children under 18 years of age, acute liver failure, decompensated cirrhosis of the liver. Prescribe with caution during exacerbation of chronic gastritis, cholecystitis, pancreatitis.
